H
Harry B. Greenberg
Researcher at Stanford University
Publications - 441
Citations - 36848
Harry B. Greenberg is an academic researcher from Stanford University. The author has contributed to research in topics: Rotavirus & Virus. The author has an hindex of 100, co-authored 433 publications receiving 34941 citations. Previous affiliations of Harry B. Greenberg include Baylor College of Medicine & United States Department of Commerce.
Papers
More filters
Journal ArticleDOI
Rescue of influenza B virus from eight plasmids
Erich Hoffmann,Kutubuddin Mahmood,Chin-Fen Yang,Robert G. Webster,Harry B. Greenberg,George Kemble +5 more
TL;DR: The results demonstrate that the eight-plasmid system can be used for the generation of high yields of influenza B virus vaccines expressing current HA and NA glycoproteins from either of the two lineages of influenza A virus.
Journal ArticleDOI
Structure of Rotavirus Outer-Layer Protein VP7 Bound with a Neutralizing Fab
Scott T. Aoki,Ethan C. Settembre,Shane D. Trask,Harry B. Greenberg,Stephen C. Harrison,Stephen C. Harrison,Philip R. Dormitzer +6 more
TL;DR: It is proposed that neutralizing antibodies against Rotavirus outer-layer protein VP7 act by stabilizing the trimer, thereby inhibiting the uncoating trigger for VP4 rearrangement and producing a potential subunit immunogen.
Journal ArticleDOI
Molecular basis of rotavirus virulence: role of gene segment 4.
TL;DR: It is found that the dose of SA-11 and NCDV rotavirus required to induce gastroenteritis in newborn mice was determined by gene segment 4.
Journal ArticleDOI
Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice.
TL;DR: B cells also play a role in clearance of primary infection but are absolutely necessary for development of immunity against rotavirus reinfection, and cytotoxic T lymphocytes are not required for this function.
Journal ArticleDOI
Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7.
TL;DR: The role of vp3 in eliciting protection against heterotypic rotav virus challenge should be considered when developing a vaccine with cloned rotavirus genes.